Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...

Deficiency of 25-hydroxyvitamin D at age 3 years is associated with more than double the risk for eosinophilic asthma in ...

Following results that have sent the stock northward, Research Capital analyst Andre Uddin remains bullish on Eupraxia ...

Eupraxia Pharmaceuticals shares rose in premarket trading Tuesday after the company said it received positive data from its eosinophilic esophagitis treatment trials. Shares traded nearly 6.3% higher ...

Eupraxia Pharmaceuticals (EPRX) announced additional positive clinical data from its ongoing RESOLVE Phase 1b/2a trial evaluating EP-104GI for ...

Eupraxia Pharmaceuticals Inc. shares T.EPRX are trading unchanged at $5.33.

Apogee Therapeutics, Inc., (Nasdaq: APGE) today announced that members of management will participate at the following investor conferences. TD Cowen 45th Annual Health Care Conference Date: Tuesday, ...

A 30-year-old New England woman’s symptoms started with a burning sensation in her feet. Over the following two days, the ...

Shares of Innergex Renewable Energy jumped 54%, to 13.40 Canadian dollars (US$9.40), after the Caisse de Depot et Placement du Quebec moved to buy the power producer in a deal that represents an ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company ...

After returning from a holiday of a lifetime, a New England woman could not understand what was up with her and neither could ...

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage ...